🔗 Share this article

As America undertakes historic changes to its vaccination schedules, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus vaccinations in the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her recent position at the FDA.

Proposed Shifts to Pediatric Vaccine Program

Agency leaders had intended to announce major revisions to the childhood vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, it is understood – a significant shift that would place the US out of alignment with much of the international standard with insufficient data for improved outcomes. The announcement has been postponed until the coming year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the meeting. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

A Shift at the FDA

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some childhood vaccine recommendations in the US in order to be more like Denmark's approach, a country with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on immunizations – typically the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no apparent experience in drug development, approval processes or management, which has been standard for past leaders of the CBER. She has worked at the FDA as a key advisor to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a large organization. She has no expertise in drug approvals.”

Past commissioners of CBER would “understand laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that previous people who led the center have had.”

The drug center has an enormous range of responsibilities at the FDA, she emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and so forth, and each of these have to be managed,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial management aspect to the job, which oversees over 5,000 staff members. “It’s a huge administrative position, if you do it right,” she said.

Agency Reaction and Disputed Policies

When asked about questions about Dr. Høeg's qualifications and whether this assignment signifies greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “concerns stem from flawed premises”.

“Her experience aligns with the duties of her role,” the spokesperson said, noting the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new priority voucher program, a controversial one-day drug-approval program that apparently worried her former heads. “By what process are these therapies being selected for this voucher program? Who takes the choices?” Howard asked. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards less stringent rules of all drugs, except for shots.”

Established History on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if problematic, past, some experts observe. She published a research paper using non-validated volunteer-provided data to assess the rate of myocarditis after Covid immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the incoming administration included altering rules for recently developed shots and halting “optional” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has allegedly proposed preventing adolescent males from receiving COVID-19 vaccines.

“She is an thorough dogmatist who commences with her conclusions and works backwards to fit the science in a very disingenuous, untruthful fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|